Atossa Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ATOS Nasdaq 8731 https://atossatherapeutics.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atossa Therapeutics Inc

We're Not Very Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Rate - Mar 30th, 2023 3:00 pm
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update - Mar 22nd, 2023 8:05 pm
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial - Mar 21st, 2023 5:19 pm
Atossa to Present at the Sidoti Small-Cap Virtual Conference - Mar 15th, 2023 1:25 pm
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer - Feb 23rd, 2023 2:15 pm
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen - Feb 13th, 2023 2:15 pm
Atossa Therapeutics Issues Letter to Shareholders - Jan 25th, 2023 2:15 pm
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations - Dec 7th, 2022 1:00 pm
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 7th, 2022 9:00 pm
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy - Nov 1st, 2022 1:15 pm
Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D. - Oct 25th, 2022 1:15 pm
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer - Oct 24th, 2022 1:15 pm
Here's Why We're Not Too Worried About Atossa Therapeutics' (NASDAQ:ATOS) Cash Burn Situation - Oct 21st, 2022 2:26 pm
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference - Sep 7th, 2022 1:00 pm
Registration Now Open for Tribe Public’s Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022 - Aug 22nd, 2022 1:30 pm
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board - Aug 18th, 2022 1:30 pm
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update - Aug 8th, 2022 8:30 pm
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers - Jul 28th, 2022 1:00 pm
Atossa: Acquiring CAR-T Company Would Be a Great Move, Says Analyst - Jul 13th, 2022 10:56 pm
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations - Jun 2nd, 2022 8:05 pm